June 07, 2026 a 04:38 pm
LLY: Analysts Ratings - Eli Lilly and Company
Eli Lilly and Company, with its impressive pharmaceutical portfolio, continues to attract a predominantly positive sentiment from analysts. The company's focus on diabetes, oncology, and autoimmune diseases provides a strong foundation for growth. With a significant number of analysts maintaining a 'Buy' or 'Strong Buy' rating, Eli Lilly appears well-positioned for potential upsides in the coming months.
Historical Stock Grades
The current month shows a steady outlook for Eli Lilly, reflecting analyst confidence with a high proportion of Buy ratings. The combination of Strong Buy and Buy significantly outweighs Hold and Sell perspectives, indicating strong market sentiment.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 18 | |
| Hold | 5 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, the total number of ratings has remained relatively stable with minor fluctuations in Hold and Strong Buy categories. Notably, the Buy ratings consistently dominate, reinforcing positive sentiment.
- Strong Buy ratings remained constant over several months.
- Hold ratings showed slight variations but no clear trend.
- Sell ratings are negligible, reflecting overall analyst confidence in the stock.
Percentage Trends
There has been a negligible shift in ratings, with a consistent strong Buy sentiment. The balance between maintaining and upgrading suggests strong and stable market confidence.
- Strong Buy percentage held steady, confirming unwavering confidence.
- Buy ratings account for approximately 60% of all recommendations.
- Hold and Sell remain low, enhancing the bullish narrative.
Latest Analyst Recommendations
Recent analyst reports reaffirm previously held positions with no major surprises. The ratings maintain a robust buy-side sentiment with no downgrades from major firms.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-05-26 | Buy | Buy | B of A Securities |
| 2026-05-05 | Overweight | Overweight | Barclays |
| 2026-05-05 | Buy | Buy | Guggenheim |
| 2026-05-04 | Outperform | Outperform | Wolfe Research |
| 2026-05-01 | Overweight | Overweight | Cantor Fitzgerald |
Analyst Recommendations with Change of Opinion
Notable changes in recommendation reflect a mix of strategic reassessments. Downgrades and upgrades provide an interesting dynamic in the stock's evaluation.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-03-17 | Reduce | Hold | HSBC |
| 2026-02-10 | Buy | Hold | Freedom Broker |
| 2025-11-10 | Hold | Buy | Freedom Broker |
| 2025-11-10 | Hold | Buy | Freedom Capital Markets |
| 2025-11-10 | Outperform | Market Perform | Leerink Partners |
Interpretation
The predominant positive sentiment towards Eli Lilly and Company denotes robust market confidence. The consistency in Buy ratings and limited downgrades point to an optimistic outlook. Nevertheless, occasional downgrades suggest careful scrutiny and market vigilance. This stability in analyst recommendations indicates trust in the company's strategic direction and market positioning.
Eli Lilly and Company's stable analyst ratings underscore a sustained faith in its market potential. The blend of steady Buy ratings coupled with occasional strategic downgrades highlights a nuanced yet confident market perspective. The minimalistic presence of Sell recommendations buttresses the firm's standing amidst investors, making it a compelling enterprise to watch.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years